These outperforming stocks are still cheap heading into 2026

U.S. equities have rebounded strongly this year and analysts highlight three outperformers with below-market forward valuations heading into 2026: CVS, Micron and Newmont. CVS has climbed ~78% YTD, reported market‑beating Q3 results, raised earnings guidance and trades at ~11x forward EPS with a 3.33% dividend and a mean target near $92 (~20% upside). Micron has nearly tripled YTD, trades around 12x forward earnings, benefits from DRAM shortages and AI demand, and carries buy-side targets up to $338 (~50% upside). Newmont, the largest gold producer, offers defensive commodity exposure at ~5x sales and a 1.1% dividend, viewed as a hedge with gold prices firm into 2026.

Analysis

Market structure: The winners are large, vertically integrated players exposed to structural tailwinds—CVS (insurance/PBM scale), Micron (DRAM tightness/AI capex), and Newmont (gold hedge). Losers include end-customers sensitive to higher input prices (cloud/data-center buyers for DRAM) and higher-cost miners without scale; retail pharmacies with weaker payer contracts face margin pressure. Supply/demand signals: DRAM inventory trough + limited new capacity implies 12–24 month above-trend pricing; gold real rates and ETF flows drive miner cash flows near term. Cross-asset: stronger gold supports miners and can pressure real yields and the dollar; semiconductor strength increases corporate capex, boosting equipment makers and capex-related credit demand, while reducing defensive bond demand if risk-on persists.

Risk assessment: Tail risks include regulatory action on PBMs/insurer margins (CVS), export controls/China curbs or a rapid DRAM demand collapse from AI spending pull-forward (MU), and a >15% drop in gold if real rates reprice (NEM). Immediate (days-weeks): momentum and technicals can overshoot; short-term (3–6 months): earnings and inventory data will reprice cyclicals; long-term (12–36 months): secular AI-driven demand supports MU but depends on capex cadence. Hidden dependencies: MU’s revenue is concentrated by product and geography (China exposure), CVS relies on policy for Medicare/Medicaid reimbursement, NEM’s cash flow tied to USD/gold correlation. Catalysts: quarterly DRAM pricing reports, Fed rate moves/CPI prints, CVS guidance cycles, and ETF gold flows.

Trade implications: Direct plays—prefer size-constrained longs: buy CVS for income+value and MU for growth, with NEM as a 1–2% defensive sleeve; expect 6–12 month timeframes. Options—use defined-risk structures: MU 6–9 month call spreads sized to 1% portfolio risk to capture a ~40–60% upside if DRAM tightness continues; sell covered calls on CVS to enhance yield (cap upside ~15–20% over 6–12 months). Relative value—pair long MU vs short cyclical foundries/legacy CPU names (e.g., INTC) to express memory tightness vs compute commoditization. Entry/exit—scale in on 5–12% pullbacks; trim on rallies exceeding target upside (CVS +15–20%, MU +40–50%, NEM +20%).

Contrarian angles: Consensus underestimates inventory-cycle risk for MU and regulatory risk for CVS; the market may be pricing momentum, not sustainable fundamentals. Micron’s +3x YTD run increases short-term mean-reversion risk—if OEM orders moderate, expect 20–40% drawdowns inside 3–6 months. Historical parallel: prior DRAM cycles (2016–18) show strong upswings followed by sharp capex-driven supply additions that crushed prices within 12–24 months. Unintended consequences: rising DRAM prices can accelerate customer capex and government scrutiny (export controls, subsidy scrutiny) that flip the narrative quickly; size positions accordingly.

Key Decisions for Investors

• Establish a 2.5% long position in CVS (NYSE: CVS) sized to portfolio risk, target a 12–20% upside to consensus $92 in 6–12 months and a covered-call overlay (sell 6–9 month calls to lock in ~10–15% annualized yield); place a hard stop-loss at -12% from entry.
• Initiate a 2% directional exposure to Micron (NASDAQ: MU) via a 6–9 month debit call spread sized to risk 1% of portfolio (defined-risk), target +40–60% return if DRAM pricing stays tight; scale out if MU appreciates >40% or if monthly DRAM spot price declines >10% sequentially.
• Add a 1–1.5% tactical hedge in Newmont (NYSE: NEM) for portfolio protection (expect to outperform in >10% equity drawdowns); buy 3–6 month puts sized to cover thy equity sleeve if gold/real rates move adverse by >150bp.
• Implement a relative-value pair: long MU (1.5%) vs short INTC (1.5%) over a 6–12 month horizon to express memory tightness vs legacy CPU weakness; widen stop to 20% on the short if NVAT/sector flows distort spreads.